Torrent Pharmaceuticals Ltd Q2 FY26 – ₹3,302 Cr Sales, 33% OPM, ₹591 Cr PAT, and an ₹11,917 Cr JB Chemicals Power Play That’s Giving Dalal Street Heartburn
1. At a Glance
Ladies and gentlemen, welcome to the great Indian pharma circus where Torrent Pharmaceuticals Ltd just rolled in with its Q2 FY26 results — a mix of serious chemistry and spicy corporate drama. The stock closed at ₹3,580, barely blinking (up just 0.75%), as if the market said, “Nice quarter bro, but what’s with that ₹11,917 crore JB Chemicals acquisition?”
Torrent Pharma, the fifth-largest player in India’s ₹2-lakh crore pharma bazaar, reported consolidated Q2 FY26 revenue of ₹3,302 crore, a YoY jump of 14.3%, with PAT soaring 32.5% to ₹591 crore. The operating margin — a healthy 33% — is proof that this company knows how to squeeze profits better than a cardiologist’s stress test.
The company sits on a ₹1.21 lakh crore market cap throne, with ROE and ROCE at a royal 26.5% and 27% respectively. Debt’s come down to ₹2,822 crore, making Torrent a recovering borrower. And while the stock trades at a dizzying P/E of 55.9x, investors still line up like patients in a government hospital, hoping for miracles.
But the headline-stealer? Torrent’s blockbuster announcement to acquire 46.39% of JB Chemicals for ₹11,917 crore — a move that screams, “We’re done being fifth, let’s aim for Sun.”
2. Introduction
If Indian pharma were a Bollywood family saga, Torrent Pharma would be the clean-cut overachiever son of the Torrent Group — the family that also sells you your electricity and city gas before handing you your heart medication.
Born from Gujarat’s fertile business soil, Torrent has grown from a mid-tier generic maker to a multinational pharmaceutical heavyweight operating in over 40 countries. From diabetes to dermatology, from cardiovascular to CNS, they’ve got a pill for every problem — except maybe their stock’s valuation.
In FY24, Branded Generics contributed 74% of total revenue, while the Generics export business added 26%, serving markets like the US, Germany, and Brazil. And let’s be clear — this isn’t just another desi pharma shop selling paracetamol. This is a chronic-therapy juggernaut with 21 of its brands among India’s Top 500, and 16 brands crossing ₹100 crore each in revenue.
Still, even powerhouses stumble. The CDSCO recently flagged Shelcal 500, Torrent’s flagship calcium supplement, in a quality alert. The company called it counterfeit — the pharmaceutical version of “That wasn’t me, boss.” Classic.
As Q2 FY26 results show, Torrent isn’t slowing down. In fact, it’s gearing up — new R&D, new facilities, and a new MD in Aman Mehta, representing Gen-Next of the Torrent dynasty. With 8 manufacturing plants, 780 scientists, and 2,500 crore dose capacity, Torrent’s lab coat is starched and ready for a global push. But can it digest its ₹11,917 crore JB Chemicals acquisition without heartburn? Let’s find out.
3. Business Model – WTF Do They Even Do?
Torrent Pharmaceuticals’ business model is as clean as its capsule coatings — but let’s unpack the pill.
At its core, the company develops, manufactures, and markets branded generics (74% of Q2 FY25 revenue) across chronic and sub-chronic therapies. This includes life-saving and life-sustaining drugs in cardiovascular, CNS, diabetes, dermatology, and gastro segments. India and Brazil form the branded pillars.
Then there’s the generics export segment (26%), which sends high-quality formulations to regulated markets like the US, Germany, and emerging nations. Essentially, Torrent takes a molecule that’s lost patent protection and mass-produces it like a college canteen serving maggi — quick, cheap, and familiar.
In the domestic market, Torrent is ranked 5th overall, and 4th in chronic/sub-chronic therapies, with a dense prescription network. Globally, it’s #1 among Indian players in Brazil, #5 in Germany’s generics market, and #11 among Indian companies in the US.
Manufacturing muscle comes from 8 Indian facilities with an API capacity of 90 MTPA and formulation capability of 2,500 crore units per annum. R&D isn’t just decoration — the company spends 5-6% of revenues there, backed by 780 scientists and 684 granted patents.
And because no modern pharma story is complete without consumer health, Torrent jumped into OTC with Shelcal, Ahaglow, Unienzyme, and Tedibar, now found in 72,000 retail outlets — basically, your nearest kirana too.
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
3,302
2,889
3,178
14.3%
3.9%
EBITDA (₹ Cr)
1,083
939
1,032
15.4%
4.9%
PAT (₹ Cr)
591
453
548
30.5%
7.8%
EPS (₹)
17.46
13.39
16.19
30.4%
7.9%
Annualized EPS = ₹69.8; at CMP ₹3,580, P/E ≈ 51x.
Torrent’s numbers look like they were prescribed a strong dose of steroids — all healthy and glowing. Margins above 30% make it a standout in Indian pharma, where price control and NPPA fines are everyday hazards.
The joke? With a 51x P/E, investors seem to believe Torrent can walk on water — or at least make money selling it.
5. Valuation Discussion – Fair Value Range Only
Let’s break it down like a pharmacist counting pills:
P/E Method: Annualized EPS = ₹69.8 Industry P/E ≈ 33x
Conservative Fair Value = ₹69.8 × 33 = ₹2,303
Optimistic (Premium Player, High ROE) = ₹69.8 × 45 = ₹3,141 👉 P/E Fair Value Range: ₹2,300 – ₹3,150
EV/EBITDA Method: EV = ₹1,23,275 Cr; EBITDA (TTM) = ₹3,993 Cr EV/EBITDA = 30.8x (current) Industry Average = ~20x
Fair EV Range (20–25x EBITDA) = ₹79,860 – ₹99,825 Cr Implying Equity Value ≈ ₹77,000 – ₹97,000 Cr 👉 Fair Value per Share: ₹2,280 – ₹2,880
DCF Method (Simplified): Assuming 12% growth for 5 years, terminal growth 4%, discount rate 10%, fair range falls around ₹2,400 – ₹3,000.
📘 Fair Value Range (Educational): ₹2,300 – ₹3,100 per share. This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Torrent is no stranger to action-packed headlines. Q2 FY26 had more drama than a family WhatsApp group during Diwali.
JB Chemicals Acquisition (₹11,917 Cr): The blockbuster. Torrent will buy 46.39% stake in JB Pharma from KKR and the Mody family,
